PMID- 26229753
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150803
LR  - 20200929
IS  - 2229-3485 (Print)
IS  - 2229-5488 (Electronic)
IS  - 2229-3485 (Linking)
VI  - 6
IP  - 3
DP  - 2015 Jul-Sep
TI  - Comparative evaluation of efficacy and safety of combination of 
      metformin-vidagliptin versus metfromin-glimepiride in most frequently used doses 
      in patients of type 2 diabetes mellitus with inadequately controlled metformin 
      monotherapy-A randomised open label study.
PG  - 163-8
LID - 10.4103/2229-3485.159942 [doi]
AB  - AIM AND OBJECTIVE: The aim was to evaluate and compare the efficacy and safety of 
      combinations of metformin-vidagliptin (MF-VG) and metfromin-glimepiride (MF-GP) 
      in type 2 diabetes mellitus (T2DM) patients. MATERIALS AND METHODS: A comparative 
      randomized open-label trial was conducted on patients with uncomplicated T2DM, on 
      treatment with MF for 4 months out of which on maximum tolerated dose of MF 
      (1000-2500 mg/day) for 4 weeks, glycosylated Haemoglobin [HbA1c]) >/=6.5%, fasting 
      blood glucose (FBG) >/=126 mg/dl and post prandial glucose (PPG) >/=200 mg/dl were 
      included in the study. Patients were randomized to receive MF (500 mg BD) + VG 
      (50 mg BD) or MF (500 mg BD) + GP (2 mg BD). RESULTS: Both the groups caused 
      significant decline in blood glucose levels both FBG as well as PPG levels (P < 
      0.01). HbA1c was also reduced significantly in both groups at 12 weeks (P < 
      0.01). Total serum cholesterol, triglycerides, low-density lipoprotein and very 
      low-density lipoprotein decreased significantly, whereas high-density lipoprotein 
      levels increased significantly from baseline levels in both the groups (P < 
      0.01). Intergroup comparison failed to demonstrate any statistical difference on 
      all of above parameters. Both weight and body mass index did not alter 
      statistically from baseline in either of the groups as well as demonstrated no 
      difference statistically on comparison (P > 0.05). At the end of the study, both 
      liver functions tests and renal functions tests remained unaltered statistically 
      and within normal clinical range in both the groups (P > 0.05). However, 
      hypoglycemia and other adverse events were numerically more in MF + GP group. 
      CONCLUSION: Both the regimens on comparison revealed similar efficacy and safety 
      thereby failing to prove superiority over each other.
FAU - Gupta, Shallini
AU  - Gupta S
AD  - Department of Pharmacology, Government Medical College, Jammu, Jammu and Kashmir, 
      India.
FAU - Khajuria, Vijay
AU  - Khajuria V
AD  - Department of Pharmacology, Government Medical College, Jammu, Jammu and Kashmir, 
      India.
FAU - Tandon, Vishal R
AU  - Tandon VR
AD  - Department of Pharmacology, Government Medical College, Jammu, Jammu and Kashmir, 
      India.
FAU - Mahajan, Annil
AU  - Mahajan A
AD  - Department of General Medicine, Government Medical College, Jammu, Jammu and 
      Kashmir, India.
FAU - Gillani, Zahid H
AU  - Gillani ZH
AD  - Department of Pharmacology, Government Medical College, Jammu, Jammu and Kashmir, 
      India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Perspect Clin Res
JT  - Perspectives in clinical research
JID - 101551517
PMC - PMC4504059
OTO - NOTNLM
OT  - Glimepiride
OT  - metformin
OT  - type-2 diabetes mellitus
OT  - vidagliptin
COIS- Conflict of Interest: None declared.
EDAT- 2015/08/01 06:00
MHDA- 2015/08/01 06:01
PMCR- 2015/07/01
CRDT- 2015/08/01 06:00
PHST- 2015/08/01 06:00 [entrez]
PHST- 2015/08/01 06:00 [pubmed]
PHST- 2015/08/01 06:01 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - PCR-6-163 [pii]
AID - 10.4103/2229-3485.159942 [doi]
PST - ppublish
SO  - Perspect Clin Res. 2015 Jul-Sep;6(3):163-8. doi: 10.4103/2229-3485.159942.